Articles

Tissue Doppler Imaging for anthracycline cardiotoxicity monitoring in pediatric patients with cancer

Cardiotoxic effects of anthracycline therapy are a major cause of morbidity for childhood cancer survivors. The aim of this retrospective evaluation is to assess the efficacy of Tissue Doppler Imaging in the e...

Authors: Francesco Venturelli, Riccardo Masetti, Marianna Fabi, Roberto Rondelli, Anna Martoni, Arcangelo Prete, Marco Bonvicini and Andrea Pession

Randomized study of doxorubicin-based chemotherapy regimens, with and without sildenafil, with analysis of intermediate cardiac markers

Doxorubicin chemotherapy is used across a range of adult and pediatric malignancies. Cardiac toxicity is common, and dysfunction develops over time in many patients. Biomarkers used for predicting late cardiac...

Authors: Andrew Poklepovic, Yuesheng Qu, Molly Dickinson, Michael C. Kontos, Maciej Kmieciak, Elizabeth Schultz, Dipankar Bandopadhyay, Xiaoyan Deng and Rakesh C. Kukreja

Do current approaches to assessing therapy related adverse events align with the needs of long-term cancer patients and survivors?

The increasing efficacy of cancer therapeutics means that the timespan of cancer therapy administration is undergoing a transition to increasingly long-term settings. Unfortunately, chronic therapy-related adv...

Authors: Syril D. Pettit and Rebecca Kirch

Use of integrated imaging and serum biomarker profiles to identify subclinical dysfunction in pediatric cancer patients treated with anthracyclines

Anthracycline induced cardiomyopathy is a major cause of mortality and morbidity among pediatric cancer survivors. It has been postulated that oxidative stress induction and inflammation may play a role in the...

Authors: Olga H. Toro-Salazar, Ji Hyun Lee, Kia N. Zellars, Paige E. Perreault, Kathryn C. Mason, Zhu Wang, Kan N. Hor, Eileen Gillan, Caroline J. Zeiss, Daniel M. Gatti, Brooke T. Davey, Shelby Kutty, Bruce T. Liang and Francis G. Spinale

Incidence and outcomes of cancer treatment-related cardiomyopathy among referrals for advanced heart failure

Approximately 2–3% of patients undergoing advanced heart failure therapies such as left ventricular assist devices (LVAD) and orthotropic heart transplantation (OHT) have chemotherapy-related cardiomyopathy, a...

Authors: Raquel Araujo-Gutierrez, Sergio H. Ibarra-Cortez, Jerry D. Estep, Arvind Bhimaraj, Ashrith Guha, Imad Hussain, Myung H. Park, Guillermo Torre-Amione and Barry H. Trachtenberg

Recurrent heart failure with preserved ejection fraction associated with carfilzomib administration for multiple myeloma

Carfilzomib, an epoxyketone proteasome inhibitor, has demonstrated improved progression-free survival in patients when used with standard treatment (lenalidomide and dexamethasone) in patients with relapsed mu...

Authors: Eric H. Yang, Cynthia Courtney, Vinisha Garg, Michael G. Fradley and Gary J. Schiller

Risk of coronary events 55 Years after Thymic irradiation in the Hempelmann cohort

Studies of cancer survivors treated with older radiotherapy (RT) techniques (pre-1990s) strongly suggest that ionizing radiation to the chest increases the risk of coronary heart disease (CHD). Our goal was to...

Authors: Michael Jacob Adams, Susan G. Fisher, Steven E. Lipshultz, Roy E. Shore, Louis S. Constine, Marilyn Stovall, Ann Dozier, Kelly Thevenet-Morrison, Robert Block, Ronald G. Schwartz and Thomas A. Pearson

Symptom practice guide for telephone assessment of patients with cancer treatment-related cardiotoxic dyspnea: Adaptation and evaluation of acceptability

Patients with cancer treatment-related cardiotoxicity, which may manifest as heart failure (HF), can present with dyspnea. Nurses frequently assess, triage and offer self-care strategies to patients experienci...

Authors: F. Kelly, S. L. Carroll, M. Carley, S. Dent, R. Shorr, J. Hu, R. Morash and D. Stacey

Cardiotoxicity and cardiovascular disease risk assessment for patients receiving breast cancer treatment

Cardiotoxicity from anticancer therapy affects heart function and structure. Cardiotoxicity can also lead to accelerated development of chronic diseases, especially in the presence of risk factors.

Authors: Robyn A. Clark, Tania S. Marin, Narelle M. Berry, John J. Atherton, Jonathon W. Foote and Bogda Koczwara

Assessment of pazopanib-related hypertension, cardiac dysfunction and identification of clinical risk factors for their development

Antineoplastic therapy with the tyrosine kinase inhibitor pazopanib in patients with advanced/metastatic renal cell carcinoma (mRCC) has been associated with hypertension (HTN), cardiomyopathy, and cardiac dys...

Authors: Daniel Pinkhas, Thai Ho and Sakima Smith

Cardiac events during treatment with proteasome inhibitor therapy for multiple myeloma

Proteasome inhibitors (PI) bortezomib and carfilzomib are cornerstone therapies for multiple myeloma. Higher incidence of cardiac adverse events (CAEs) has been reported in patients receiving carfilzomib. Howe...

Authors: John H. Chen, Daniel J. Lenihan, Sharon E. Phillips, Shelton L. Harrell and Robert F. Cornell

Exercise intensity in cancer survivors: a matter of the heart

Authors: Stephanie M. Smith and Joseph R. Carver

Management of atrial fibrillation in patients taking targeted cancer therapies

Atrial fibrillation (AF) is frequently observed in patients being treated for cancer and can lead to increased morbidity and mortality in this population. With the use of newer, targeted cancer therapies, seve...

Authors: Aarti Asnani, Anastasia Manning, Moussa Mansour, Jeremy Ruskin, Ephraim P. Hochberg and Leon M. Ptaszek

Crizotinib inhibits hyperpolarization-activated cyclic nucleotide-gated channel 4 activity

Sinus bradycardia is frequently observed in patients treated with crizotinib, a receptor tyrosine kinase inhibitor used for the treatment of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung canc...

Authors: Zhushan Zhang, Tai-Qin Huang, Igor Nepliouev, Hengtao Zhang, Adam S. Barnett, Paul B. Rosenberg, Sai-Hong I. Ou and Jonathan A. Stiber

Cardiovascular co-morbidity in cancer patients: the role of psychological distress

Due to aging of the population and cardiotoxic cancer treatment, there is an increasing group of patients with cancer and co-morbid cardiovascular disease (CVD). In order to find a balance between the risk of ...

Authors: Dounya Schoormans, Susanne S. Pedersen, Susanne Dalton, Nina Rottmann and Lonneke van de Poll-Franse

Juvenile competitive triathlete after cardiotoxic anthracycline therapy for Acute Myeloid Leukemia

The treatment of Acute Myeloid Leukemia (AML) leads to several functional limitations. Especially cardiac burden following cardiotoxic chemotherapy, which limits exercise and competitive sport in the long-term...

Authors: Pia von Korn, Manfred Vogt, Renate Oberhoffer, Peter Ewert and Jan Müller

A comparative assessment of coronary artery calcification on chest CT scans of patients referred to a cardio-oncology clinic

The presence and burden of coronary artery calcium (CAC) is a strong predictor of cardiovascular events. In an effort to gain insight into the utility of CAC for coronary artery disease (CAD) screening in canc...

Authors: Alison M. Brann, Charlotte J. Bai, John F. Hibbeln, Kim A. Williams and Tochi M. Okwuosa

Persistent PR segment change in malignant pericardial disease

Electrocardiographic changes may manifest in patients with pericardial effusions. PR segment changes are frequently overlooked, but when present, can provide diagnostic significance. The diagnostic value of PR...

Authors: M. Ahluwalia, R. O’Quinn, B. Ky, D. Callans, J. Kucharczuk and J. R. Carver

Rationale for setting up a cardio-oncology unit: our experience at Mayo Clinic

The diagnosis and management of cardiovascular complications have become a clinical concern for oncologists, cardiologists, surgeons, interventional radiologists, radiation therapy physicians, internists, nurs...

Authors: Sergio Barros-Gomes, Joerg Herrmann, Sharon L. Mulvagh, Amir Lerman, Grace Lin and Hector R. Villarraga

The interplay between genetic background and sexual dimorphism of doxorubicin-induced cardiotoxicity

Doxorubicin (DOX) is a very effective anticancer medication that is commonly used to treat hematological malignancies and solid tumors. Nevertheless, DOX is known to have cardiotoxic effects that may lead to c...

Authors: Beshay N. Zordoky, M. Judith Radin, Lois Heller, Anthony Tobias, Ilze Matise, Fred S. Apple, Sylvia A. McCune and Leslie C. Sharkey

Targeting endothelial cell metabolism for cardio-protection from the toxicity of antitumor agents

The vascular endothelium plays a fundamental role in the maintenance of tissue homeostasis, regulating local blood flow and other physiological processes. Chemotherapeutic drugs and target therapies, including...

Authors: Lucia Morbidelli, Sandra Donnini and Marina Ziche

Doxorubicin cardiotoxicity and target cells: a broader perspective

The cardiotoxicity of doxorubicin is becoming an interdisciplinary point of interest given a growing population of cancer survivors. The complex and not completely understood pathogenesis of this complication ...

Authors: Antonella De Angelis, Konrad Urbanek, Donato Cappetta, Elena Piegari, Loreta Pia Ciuffreda, Alessia Rivellino, Rosa Russo, Grazia Esposito, Francesco Rossi and Liberato Berrino

Breast cancer treatment-associated cardiovascular toxicity and effects of exercise countermeasures

Advances in breast cancer treatment have improved disease-free survival and overall survival in women with early-stage breast cancer. However, these improvements may be attenuated by the adverse cardiovascular...

Authors: Anthony F. Yu and Lee W. Jones

Hypertension in cancer patients treated with anti-angiogenic based regimens

New anti-cancer drugs that inhibit the vascular endothelial growth factor (VEGF) signaling pathway are highly effective in the treatment of solid tumors, however concerns remain regarding their cardiovascular ...

Authors: Yishay Wasserstrum, Ran Kornowski, Pia Raanani, Avi Leader, Oren Pasvolsky and Zaza Iakobishvili

Tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia

Tyrosine kinase inhibitors (TKIs) have revolutionized the management and outcomes of chronic myeloid leukemia (CML) patients. Improved disease control and prolonged life expectancy now mandate focus on improvi...

Authors: Oren Pasvolsky, Avi Leader, Zaza Iakobishvili, Yishay Wasserstrum, Ran Kornowski and Pia Raanani

Low dose radiation and circulatory diseases: a brief narrative review

Exposure to high doses of ionizing radiation is associated with damage to the heart and coronary arteries. However, only recently have studies with high-quality individual dosimetry data allowed this risk to b...

Authors: Mark P. Little and Steven E. Lipshultz

An Invitation from the Editors of Cardio-Oncology

Authors: Steven E. Lipshultz, Giorgio Minotti, Joseph Carver and Vivian I. Franco

Cardiac safety of afatinib: a review of data from clinical trials

Afatinib is an oral irreversible ErbB family blocker that targets epidermal growth factor receptor (EGFR/ErbB1), human epidermal growth factor receptor 2 (HER2/ErbB2), and HER4 (ErbB4) and is approved for the ...

Authors: Michael S. Ewer, Kalpesh Patel, Dennis O’Brien and Robert M. Lorence

Effect of myocardial dysfunction in cardiac morbidity and all cause mortality in childhood cancer subjects treated with anthracycline therapy

Subacute cardiotoxicity, consisting of acute myocyte damage and associated left ventricular dysfunction, occurs early during anthracycline therapy. We investigated the impact of myocardial dysfunction, defined...

Authors: Olga H. Toro-Salazar, Eileen Gillan, Joanna Ferranti, Andrea Orsey, Karen Rubin, Shailendra Upadhyay, Wojciech Mazur and Kan N. Hor